49 related articles for article (PubMed ID: 28988588)
1. Echocardiographic characteristics of patients with acute heart failure requiring tolvaptan: a retrospective study.
Nakada Y; Okayama S; Nakano T; Ueda T; Onoue K; Takeda Y; Kawakami R; Horii M; Uemura S; Fujimoto S; Saito Y
Cardiovasc Ultrasound; 2015 Jun; 13():27. PubMed ID: 26049727
[TBL] [Abstract][Full Text] [Related]
2. Effects of door-to-tolvaptan time on short-term clinical outcome in patients with acute heart failure.
Nomura R; Morishita T; Sato Y; Aoyama D; Shimizu T; Uzui H; Nakano A; Tada H
ESC Heart Fail; 2023 Dec; 10(6):3573-3581. PubMed ID: 37752742
[TBL] [Abstract][Full Text] [Related]
3. Effects of recombinant human brain natriuretic peptide combined with tolvaptan on cardiac and renal function and serum inflammatory factors in patients with severe heart failure.
Yang J; Zhang L; Guo M; Hao M
Medicine (Baltimore); 2023 Nov; 102(45):e35900. PubMed ID: 37960770
[TBL] [Abstract][Full Text] [Related]
4. Volume markers in left ventricular diastolic dysfunction and adverse outcomes in peritoneal dialysis patients: a prospective cohort study.
Xiang S; Zuo M; Deng Y; Luo X; Dong Q; Chen J; Siu CW; Yin L
Sci Rep; 2023 Oct; 13(1):16892. PubMed ID: 37803046
[TBL] [Abstract][Full Text] [Related]
5. Impact of Goreisan upon aquaporin-2-incorporated aquaresis system in patients with congestive heart failure.
Kakeshita K; Imamura T; Onoda H; Kinugawa K
CEN Case Rep; 2023 Feb; 12(1):73-77. PubMed ID: 35895224
[TBL] [Abstract][Full Text] [Related]
6. Comparing Left Ventricular Diastolic Function between Peritoneal Dialysis and Non-Dialysis Patients with Stage 5 Chronic Kidney Disease: A Propensity Score-Matched Analysis.
Han BG; Seol JH; Choi S; Shin D; Kim JS; Kim YH
J Clin Med; 2023 Aug; 12(15):. PubMed ID: 37568494
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the Effects of Carperitide and Tolvaptan on Patients with Left Ventricular Dysfunction: A Two-Center Retrospective Study.
Koeda C; Yamaya S; Hozawa M; Sato M; Nasu K; Takahashi T; Terui K
Cardiol Res Pract; 2017; 2017():6935342. PubMed ID: 28785506
[TBL] [Abstract][Full Text] [Related]
8. Short-term impact of kampo goreisan in patients with congestive heart failure refractory to tolvaptan-incorporated medical therapy.
Hida Y; Imamura T; Onoda H; Kakeshita K; Kinugawa K
Heart Vessels; 2024 Jun; ():. PubMed ID: 38904671
[TBL] [Abstract][Full Text] [Related]
9. Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction.
Januzzi JL; Prescott MF; Butler J; Felker GM; Maisel AS; McCague K; Camacho A; Piña IL; Rocha RA; Shah AM; Williamson KM; Solomon SD;
JAMA; 2019 Sep; 322(11):1085-1095. PubMed ID: 31475295
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.
Velazquez EJ; Morrow DA; DeVore AD; Duffy CI; Ambrosy AP; McCague K; Rocha R; Braunwald E;
N Engl J Med; 2019 Feb; 380(6):539-548. PubMed ID: 30415601
[TBL] [Abstract][Full Text] [Related]
11. A Case of Hepatitis E Virus Infection: One of Differential Diagnosis of Liver Injury in Patients Undergoing Peritoneal Dialysis.
Yan T; Sakai Y; Terada K; Okano S; Kawasaki S; Kashiwagi T; Iwabu M
Int Med Case Rep J; 2022; 15():557-561. PubMed ID: 36245962
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of triple diuretic treatment in continuous ambulatory peritoneal dialysis patients: A randomized controlled trial.
Witoon R; Yongsiri S; Buranaburidej P; Nanna P
Kidney Res Clin Pract; 2019 Mar; 38(1):108-115. PubMed ID: 30798586
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the effects of tolvaptan and furosemide on renal water and sodium excretion in patients with heart failure and advanced chronic kidney disease: a subanalysis of the K-STAR study.
Tominaga N; Kida K; Inomata T; Sato N; Izumi T; Akashi YJ; Shibagaki Y
Clin Exp Nephrol; 2018 Dec; 22(6):1395-1403. PubMed ID: 29934667
[TBL] [Abstract][Full Text] [Related]
14. Role of Chronic Use of Tolvaptan in Patients with Heart Failure Undergoing Peritoneal Dialysis.
Mori T; Kurasawa N; Ohsaki Y; Koizumi K; Sato S; Oba-Yabana I; Shimada S; Sato E; Naganuma E; Tsuchikawa M; Ito S
Adv Perit Dial; 2016; 32():39-45. PubMed ID: 28988588
[TBL] [Abstract][Full Text] [Related]
15. Beneficial role of tolvaptan in the control of body fluids without reductions in residual renal function in patients undergoing peritoneal dialysis.
Mori T; Oba I; Koizumi K; Kodama M; Shimanuki M; Tanno M; Chida M; Saito M; Kiyomoto H; Miyazaki M; Ogawa S; Sato H; Ito S
Adv Perit Dial; 2013; 29():33-7. PubMed ID: 24344488
[TBL] [Abstract][Full Text] [Related]
16. Dual Impact of Tolvaptan on Intracellular and Extracellular Water in Chronic Kidney Disease Patients with Fluid Retention.
Masuda T; Murakami T; Igarashi Y; Okabe K; Kobayashi T; Takeda SI; Saito T; Sekiguchi C; Miyazawa Y; Akimoto T; Saito O; Muto S; Nagata D
Intern Med; 2016; 55(19):2759-2764. PubMed ID: 27725533
[TBL] [Abstract][Full Text] [Related]
17. A Pilot Study Examining the Effects of Tolvaptan on Residual Renal Function in Peritoneal Dialysis for Diabetics.
Hiramatsu T; Hobo A; Hayasaki T; Kabu K; Furuta S
Perit Dial Int; 2015; 35(5):552-8. PubMed ID: 25082843
[TBL] [Abstract][Full Text] [Related]
18. Urine Aquaporin-2: A Promising Marker of Response to the Arginine Vasopressin Type-2 Antagonist, Tolvaptan in Patients with Congestive Heart Failure.
Imamura T; Kinugawa K
Int J Mol Sci; 2016 Jan; 17(1):. PubMed ID: 26784173
[TBL] [Abstract][Full Text] [Related]
19. Tolvaptan for Heart Failure in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis.
Sen J; Chung E; McGill D
Heart Lung Circ; 2018 Aug; 27(8):928-939. PubMed ID: 29602756
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
